Dr. Marty Makary is resigning from his role as commissioner of the Food and Drug Administration, according to an Associated Press report, just over a year after his confirmation in March 2025.
Makary’s resignation comes after disagreement with anti-abortion groups, vaping advocates and executives in the health industry, according to the AP.
The moves preceding Makary’s resignation
Makary has faced pushback concerning his recent efforts in his role.
He was accused of stalling an internal review of mifepristone, a mail-order abortion pill. This claim caused dispute with pro-life activists, such as Marjorie Dannenfelser, president of the Susan B. Anthony Pro-Life America.
“We look forward to a new FDS commissioner who will put an end to the mail-order abortion drug regime,” Dannenfelser said.
Vaping lobbyists also were critical of Makary after he initially blocked the authorization of flavored vapes. Makary later authorized them, but those opposed to his actions were still unsettled.
Also, initiatives from Makary aimed at speeding up FDA drug reviews drew criticism from some pharmaceutical executives.
Trump weighs in
When asked by reporters, President Donald Trump did not say whether he asked Makary to resign, but he did compliment Makary’s character.
“Marty is a great guy,” Trump said. “He was having some difficulty ... but he’s going to go on and he’s going to do well.”
Kyle Diamantas, the FDA’s deputy commissioner for food, is expected to temporarily take over as acting commissioner. Diamantas is an attorney with personal ties to Donald Trump Jr., AP reports.
Trump referred to Diamantas as “a very talented person” in a post on Truth Social.
A permanent replacement will require nomination by Trump and confirmation by the Senate.